“山西最牛上市公司”半年报！上市两年，市值增了280多亿

Core Viewpoint - Jinbo Biological has reported strong financial performance for the first half of the year, indicating significant growth in revenue and net profit, alongside a planned cash dividend distribution to shareholders [1][2][3]. Financial Performance - The company achieved a revenue of 859 million yuan, representing a year-on-year increase of 42.43% [2]. - The net profit attributable to shareholders was 392 million yuan, reflecting a year-on-year growth of 26.65% [2]. - The gross profit margin decreased slightly to 90.68% from 91.58% in the previous year [2]. - Basic earnings per share were reported at 3.41 yuan [2]. Business Growth Drivers - The revenue growth was primarily driven by increased sales in medical devices and functional skincare products [2]. - The medical device segment saw growth mainly from the sales of implant products based on type A recombinant human collagen [2]. - The functional skincare segment benefited from the sales of proprietary brands such as "重源" and "ProtYouth®" [2]. Company Background - Jinbo Biological is recognized as a national-level specialized and innovative "little giant" enterprise and a key player in the synthetic biology industry chain in Shanxi Province [3]. - The company was listed on the Beijing Stock Exchange on July 20, 2023, with an initial market capitalization of 8.757 billion yuan, which has since increased to nearly 37 billion yuan [3]. Future Prospects - The company plans to utilize funds from a recent share transfer to enhance its research and development capabilities, particularly in the area of humanized collagen products [6][7]. - The total investment for the new FAST database and product development platform project is approximately 1.26 billion yuan, with a three-year implementation period [6].